Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8981 results

  1. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued Reference number: GID-NG10385

    NICE guideline
    Discontinued

  3. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued Reference number: GID-NG10395

    NICE guideline
    Discontinued

  4. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

    NICE guideline
    Discontinued

  5. Surgical site infections: prevention and treatment - Update

    Discontinued Reference number: GID-NG10374

    NICE guideline
    Discontinued

  6. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued Reference number: GID-TA11171

    Technology appraisal guidance
    Discontinued

  7. Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1140).

    Withdrawn guidance

  8. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    This guidance has been updated and replaced by NICE HealthTech guidance 668.

    Withdrawn guidance

  9. Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

    In development Reference number: GID-TA10467 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued Reference number: GID-TA10522

    Technology appraisal guidance
    Discontinued

  11. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development Reference number: GID-TA10592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued Reference number: GID-TA10525

    Technology appraisal guidance
    Discontinued

  13. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued Reference number: GID-TA10316

    Technology appraisal guidance
    Discontinued

  14. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development Reference number: GID-TA10800 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued